Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling - PubMed (original) (raw)
. 2004 Sep 17;279(38):39915-24.
doi: 10.1074/jbc.M404795200. Epub 2004 Jun 24.
Affiliations
- PMID: 15218027
- DOI: 10.1074/jbc.M404795200
Free article
Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling
Daniel Kirchhofer et al. J Biol Chem. 2004.
Free article
Abstract
Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the ligand for Met, a receptor tyrosine kinase implicated in development, tissue regeneration, and invasive tumor growth. HGF acquires signaling activity only upon proteolytic cleavage of single-chain HGF into its alpha/beta heterodimer, similar to zymogen activation of structurally related serine proteases. Although both chains are required for activation, only the alpha-chain binds Met with high affinity. Recently, we reported that the protease-like HGF beta-chain binds to Met with low affinity (Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D., and Wiesmann, C. (2004) EMBO J. 23, 2325-2335). Here we demonstrate that the zymogen-like form of HGF beta also binds Met, albeit with 14-fold lower affinity than the protease-like form, suggesting optimal interactions result from conformational changes upon cleavage of the single-chain form. Extensive mutagenesis of the HGF beta region corresponding to the active site and activation domain of serine proteases showed that 17 of the 38 purified two-chain HGF mutants resulted in impaired cell migration or Met phosphorylation but no loss in Met binding. However, reduced biological activities were well correlated with reduced Met binding of corresponding mutants of HGF beta itself in assays eliminating dominant alpha-chain binding contributions. Moreover, the crystal structure of HGF beta determined at 2.53 A resolution provides a structural context for the mutagenesis data. The functional Met binding site is centered on the "active site region" including "triad" residues Gln(534) [c57], Asp(578) [c102], and Tyr(673) [c195] and neighboring "activation domain" residues Val(692), Pro(693), Gly(694), Arg(695), and Gly(696) [c214-c219]. Together they define a region that bears remarkable resemblance to substrate processing regions of serine proteases. Models of HGF-dependent Met receptor activation are discussed.
Similar articles
- Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA. Kirchhofer D, et al. Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5306-11. doi: 10.1073/pnas.0700184104. Epub 2007 Mar 19. Proc Natl Acad Sci U S A. 2007. PMID: 17372204 Free PMC article. - Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling.
Landgraf KE, Santell L, Billeci KL, Quan C, Young JC, Maun HR, Kirchhofer D, Lazarus RA. Landgraf KE, et al. J Biol Chem. 2010 Dec 17;285(51):40362-72. doi: 10.1074/jbc.M110.179721. Epub 2010 Oct 11. J Biol Chem. 2010. PMID: 20937841 Free PMC article. - Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.
Peek M, Moran P, Mendoza N, Wickramasinghe D, Kirchhofer D. Peek M, et al. J Biol Chem. 2002 Dec 6;277(49):47804-9. doi: 10.1074/jbc.M209778200. Epub 2002 Oct 7. J Biol Chem. 2002. PMID: 12372819 - Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.
Bardelli A, Ponzetto C, Comoglio PM. Bardelli A, et al. J Biotechnol. 1994 Sep 30;37(2):109-22. doi: 10.1016/0168-1656(94)90002-7. J Biotechnol. 1994. PMID: 7765452 Review. - Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.
Maun HR, Kirchhofer D, Lazarus RA. Maun HR, et al. Biol Chem. 2010 Aug;391(8):881-92. doi: 10.1515/BC.2010.098. Biol Chem. 2010. PMID: 20536384 Review.
Cited by
- State of the structure address on MET receptor activation by HGF.
Linossi EM, Estevam GO, Oshima M, Fraser JS, Collisson EA, Jura N. Linossi EM, et al. Biochem Soc Trans. 2021 Apr 30;49(2):645-661. doi: 10.1042/BST20200394. Biochem Soc Trans. 2021. PMID: 33860789 Free PMC article. Review. - Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.
Goyette P, Lefebvre C, Ng A, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Latiano A, Aumais G, Deslandres C, Jobin G, Annese V, Daly MJ, Xavier RJ, Rioux JD. Goyette P, et al. Mucosal Immunol. 2008 Mar;1(2):131-8. doi: 10.1038/mi.2007.15. Epub 2008 Jan 16. Mucosal Immunol. 2008. PMID: 19079170 Free PMC article. - Contemporaneous Perioperative Inflammatory and Angiogenic Cytokine Profiles of Surgical Breast, Colorectal, and Prostate Cancer Patients: Clinical Implications.
Baghaie L, Haxho F, Leroy F, Lewis B, Wawer A, Minhas S, Harless WW, Szewczuk MR. Baghaie L, et al. Cells. 2023 Dec 4;12(23):2767. doi: 10.3390/cells12232767. Cells. 2023. PMID: 38067195 Free PMC article. - An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice.
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. Mazzone M, et al. J Clin Invest. 2004 Nov;114(10):1418-32. doi: 10.1172/JCI22235. J Clin Invest. 2004. PMID: 15545993 Free PMC article. - Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.
Desole C, Gallo S, Vitacolonna A, Vigna E, Basilico C, Montarolo F, Zuppini F, Casanova E, Miggiano R, Ferraris DM, Bertolotto A, Comoglio PM, Crepaldi T. Desole C, et al. Front Immunol. 2021 Dec 3;12:775151. doi: 10.3389/fimmu.2021.775151. eCollection 2021. Front Immunol. 2021. PMID: 34925346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous